[ad_1]
* Plant producing treatment of epilepsy valproate
* Complaint filed by France Nature Environment (Recasting of production stopped)
By Matthias Blamont
PARIS, July 9 (Reuters) – Sanofi stopped production plant in the French Pyrenees after an environmental body filed a complaint against what he said was a massive air pollution.
France Nature Environment, a federation representing some 3,500 local associations, said Sunday that pollutant emissions from Sanofi's plant in Mourenx France, which produces the valproate for treatment of epilepsy, was 7,000 times the limit allowed by French law.
The organization is particularly concerned about bromopropane, a widely used solvent whose emissions exceeded 190,000 and 90,000 tests performed in March and October of last year.
It is not known how long the pollution has occurred.
"S anofi Chimie decided to stop production at its Mourenx site from today and proceed with the announced technical improvements," said a spokesman for Sanofi in an email release
.
Sanofi also claimed to have asked an independent organization to assess the potential effects on local populations. The study, said Sanofi, revealed that they had not been exposed to increased risk, although the spokesman refused to provide access to the company. study.
France Nature Environnement says that bromopropane can cause respiratory and skin infections. ] Sanofi epilepsy, sold under the brand name Depakine for epilepsy and Depakote and Depamide for bipolar disorder, has been the subject of sanitary fears in several countries due to the lack of medical care. information on the risks associated with active valproate taken during pregnancy
The information provided with valproate has long included a warning about the possible risk of congenital malformations, but this has not prevented up to 4,100 children in France to suffer serious malformations between 1967 and 2016, officials said in 2017.
Depakine, who lost his patent in 1998, is prescribed in more than 100 countries. (Report by Matthias Blamont, edited by Michel Rose and David Goodman)
Our Standards: The Principles of Thomson Reuters Trust.
Source link
